Literature DB >> 35338366

Can drugs reduce the risk of long COVID? What scientists know so far.

Heidi Ledford.   

Abstract

Entities:  

Keywords:  Immunology; Infection; Medical research; SARS-CoV-2

Mesh：

Year:  2022        PMID： 35338366     DOI： 10.1038/d41586-022-00823-y

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  3 in total

1.  Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial.

Authors:  Olli P O Nevalainen; Saana Horstia; Sanna Laakkonen; Jarno Rutanen; Jussi M J Mustonen; Ilkka E J Kalliala; Hanna Ansakorpi; Hanna-Riikka Kreivi; Pauliina Kuutti; Juuso Paajanen; Seppo Parkkila; Erja-Leena Paukkeri; Markus Perola; Negar Pourjamal; Andreas Renner; Tuomas Rosberg; Taija Rutanen; Joni Savolainen; Jari K Haukka; Gordon H Guyatt; Kari A O Tikkinen
Journal:  Nat Commun       Date:  2022-10-18       Impact factor: 17.694

2.  Resurrecting Epstein-Barr Virus.

Authors:  Roberto Paganelli
Journal:  Pathogens       Date:  2022-07-06

Review 3.  The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.

Authors:  Douglas B Kell; Etheresia Pretorius
Journal:  Biochem J       Date:  2022-08-31       Impact factor: 3.766
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.